CEFOXITIN (cefoxitin) by Hikma is mechanism of action cefoxitin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Approved for serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below, infection in patients undergoing uncontaminated gastrointestinal surgery, vaginal hysterectomy and 2 more indications. First approved in 2010.
Drug data last refreshed 21h ago
Mechanism of Action Cefoxitin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefoxitin has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.
Worked on CEFOXITIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo